154 related articles for article (PubMed ID: 9128836)
1. 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations.
Miller RT; Lau SS; Monks TJ
Eur J Pharmacol; 1997 Apr; 323(2-3):173-80. PubMed ID: 9128836
[TBL] [Abstract][Full Text] [Related]
2. Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity.
Bai F; Lau SS; Monks TJ
Chem Res Toxicol; 1999 Dec; 12(12):1150-7. PubMed ID: 10604863
[TBL] [Abstract][Full Text] [Related]
3. Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats.
Miller RT; Lau SS; Monks TJ
Chem Res Toxicol; 1996 Mar; 9(2):457-65. PubMed ID: 8839050
[TBL] [Abstract][Full Text] [Related]
4. Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase.
Bai F; Jones DC; Lau SS; Monks TJ
Chem Res Toxicol; 2001 Jul; 14(7):863-70. PubMed ID: 11453733
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy).
Easton N; Fry J; O'Shea E; Watkins A; Kingston S; Marsden CA
Brain Res; 2003 Oct; 987(2):144-54. PubMed ID: 14499958
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of 5-(glutathion-S-yl)-alpha-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats.
Miller RT; Lau SS; Monks TJ
Chem Res Toxicol; 1995; 8(5):634-41. PubMed ID: 7548745
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates.
Carvalho M; Milhazes N; Remião F; Borges F; Fernandes E; Amado F; Monks TJ; Carvalho F; Bastos ML
Arch Toxicol; 2004 Jan; 78(1):16-24. PubMed ID: 14586543
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of neurotoxic thioether metabolites of 3,4-(+/-)-methylenedioxymethamphetamine in rat brain.
Erives GV; Lau SS; Monks TJ
J Pharmacol Exp Ther; 2008 Jan; 324(1):284-91. PubMed ID: 17906065
[TBL] [Abstract][Full Text] [Related]
9. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells.
Jones DC; Lau SS; Monks TJ
J Pharmacol Exp Ther; 2004 Oct; 311(1):298-306. PubMed ID: 15169827
[TBL] [Abstract][Full Text] [Related]
10. Glial cell response to 3,4-(+/-)-methylenedioxymethamphetamine and its metabolites.
Herndon JM; Cholanians AB; Lau SS; Monks TJ
Toxicol Sci; 2014 Mar; 138(1):130-8. PubMed ID: 24299738
[TBL] [Abstract][Full Text] [Related]
11. Major metabolites of (+/-)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons.
McCann UD; Ricaurte GA
Brain Res; 1991 Apr; 545(1-2):279-82. PubMed ID: 1860050
[TBL] [Abstract][Full Text] [Related]
12. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain.
Jones DC; Duvauchelle C; Ikegami A; Olsen CM; Lau SS; de la Torre R; Monks TJ
J Pharmacol Exp Ther; 2005 Apr; 313(1):422-31. PubMed ID: 15634943
[TBL] [Abstract][Full Text] [Related]
13. The neurochemical and stimulatory effects of putative metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in rats.
Yeh SY; Hsu FL
Pharmacol Biochem Behav; 1991 Jul; 39(3):787-90. PubMed ID: 1723801
[TBL] [Abstract][Full Text] [Related]
14. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro.
Carvalho M; Remião F; Milhazes N; Borges F; Fernandes E; Monteiro Mdo C; Gonçalves MJ; Seabra V; Amado F; Carvalho F; Bastos ML
Chem Res Toxicol; 2004 May; 17(5):623-32. PubMed ID: 15144219
[TBL] [Abstract][Full Text] [Related]
15. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity.
Monks TJ; Jones DC; Bai F; Lau SS
Ther Drug Monit; 2004 Apr; 26(2):132-6. PubMed ID: 15228153
[TBL] [Abstract][Full Text] [Related]
16. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
Colado MI; Williams JL; Green AR
Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557
[TBL] [Abstract][Full Text] [Related]
17. Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes.
Barbosa DJ; Capela JP; Oliveira JM; Silva R; Ferreira LM; Siopa F; Branco PS; Fernandes E; Duarte JA; de Lourdes Bastos M; Carvalho F
Br J Pharmacol; 2012 Feb; 165(4b):1017-33. PubMed ID: 21506960
[TBL] [Abstract][Full Text] [Related]
18. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells.
Carvalho M; Hawksworth G; Milhazes N; Borges F; Monks TJ; Fernandes E; Carvalho F; Bastos ML
Arch Toxicol; 2002 Oct; 76(10):581-8. PubMed ID: 12373454
[TBL] [Abstract][Full Text] [Related]
19. Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity.
Escubedo E; Abad S; Torres I; Camarasa J; Pubill D
Neurochem Int; 2011 Jan; 58(1):92-101. PubMed ID: 21074589
[TBL] [Abstract][Full Text] [Related]
20. Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.
Mueller M; Yuan J; Felim A; Neudörffer A; Peters FT; Maurer HH; McCann UD; Largeron M; Ricaurte GA
Drug Metab Dispos; 2009 Oct; 37(10):2079-86. PubMed ID: 19628751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
